Department of Neurology, Mayo Clinic, 200 First Street SW,Rochester, MN 55905, USA.
Am J Epidemiol. 2011 Sep 1;174(5):574-81. doi: 10.1093/aje/kwr124. Epub 2011 Jul 8.
Glioma risk has consistently been inversely associated with allergy history but not with smoking history despite putative biologic plausibility. Data from 855 high-grade glioma cases and 1,160 controls from 4 geographic regions of the United States during 1997-2008 were analyzed for interactions between allergy and smoking histories and inherited variants in 5 established glioma risk regions: 5p15.3 (TERT), 8q24.21 (CCDC26/MLZE), 9p21.3 (CDKN2B), 11q23.3 (PHLDB1/DDX6), and 20q13.3 (RTEL1). The inverse relation between allergy and glioma was stronger among those who did not (odds ratio(allergy-glioma) = 0.40, 95% confidence interval: 0.28, 0.58) versus those who did (odds ratio(allergy-glioma) = 0.76, 95% confidence interval: 0.59, 0.97; P(interaction) = 0.02) carry the 9p21.3 risk allele. However, the inverse association with allergy was stronger among those who carried (odds ratio(allergy-glioma) = 0.44, 95% confidence interval: 0.29, 0.68) versus those who did not carry (odds ratio(allergy-glioma) = 0.68, 95% confidence interval: 0.54, 0.86) the 20q13.3 glioma risk allele, but this interaction was not statistically significant (P = 0.14). No relation was observed between glioma risk and smoking (odds ratio = 0.92, 95% confidence interval: 0.77, 1.10; P = 0.37), and there were no interactions for glioma risk of smoking history with any of the risk alleles. The authors' observations are consistent with a recent report that the inherited glioma risk variants in chromosome regions 9p21.3 and 20q13.3 may modify the inverse association of allergy and glioma.
尽管存在潜在的生物学合理性,但胶质瘤风险一直与过敏史呈负相关,而与吸烟史无关。分析了 1997 年至 2008 年间来自美国 4 个地区的 855 名高级别胶质瘤病例和 1160 名对照者的数据,以研究过敏和吸烟史与 5 个已确定的胶质瘤风险区域(5p15.3[TERT]、8q24.21[CCDC26/MLZE]、9p21.3[CDKN2B]、11q23.3[PHLDB1/DDX6]和 20q13.3[RTEL1])中遗传变异之间的相互作用。在未携带 9p21.3 风险等位基因的患者中(比值比(过敏-胶质瘤)=0.40,95%置信区间:0.28,0.58),过敏与胶质瘤之间的反比关系更强,而在携带 9p21.3 风险等位基因的患者中(比值比(过敏-胶质瘤)=0.76,95%置信区间:0.59,0.97;P(交互)=0.02)。然而,在携带 20q13.3 胶质瘤风险等位基因的患者中(比值比(过敏-胶质瘤)=0.44,95%置信区间:0.29,0.68),与未携带该基因的患者相比(比值比(过敏-胶质瘤)=0.68,95%置信区间:0.54,0.86),过敏与胶质瘤之间的反比关系更强,但这种相互作用无统计学意义(P=0.14)。作者的观察结果与最近的一项报告一致,即染色体区域 9p21.3 和 20q13.3 中的遗传胶质瘤风险变异可能会改变过敏与胶质瘤之间的反比关系。
Am J Epidemiol. 2011-7-8
Am J Epidemiol. 2010-5-12
Cancer Genet. 2011-1
Clin Cancer Res. 2010-9-16
Hum Genet. 2012-8-11
Acta Neurochir (Wien). 2025-4-21
Cancers (Basel). 2022-5-13
Tob Induc Dis. 2021-5-10
Neuro Oncol. 2020-11-26
Cancers (Basel). 2019-3-22
Clin Neurol Neurosurg. 2019-2
Neurosciences (Riyadh). 2018-7
Cancer Genet. 2011-1
Cytokine Growth Factor Rev. 2010-6-2
Am J Epidemiol. 2010-5-12
Neuro Oncol. 2010-2-5
Am J Epidemiol. 2010-3-12
Cancer Res. 2009-8-15